Letter to JAMA editor discussing colon cancer screening

Posted on November 04 2016 by J Seabrook

Dr Nicholas T. Potter Executive Vice President of Clinical Affairs at Molecular Pathology Laboratory Network Inc (MPLN), in a recent letter to the editor of Journal of the American Medical Association (JAMA) Oct 25 2016, clarified the performance…
Read more


MPLN expands their oncology offering in CLL/SLL with IgVH Somatic Hypermutation by NGS

Posted on October 19 2016 by Jonathan Mulkey

CLL/SLL is the most common leukemia diagnosed among adults in Western countries and is associated with heterogeneous clinical outcomes.  IgVH somatic hypermutation (SHM) status is a primary component of the CLL International Prognostic Index…
Read more

New Legislation for Blood Based Testing for Colorectal Cancer Screening

Posted on October 10 2016 by J Seabrook

The 'Donald Payne Sr. Colorectal Cancer Detection Act of 2016" was introduced by Congressman Donald M. Payne, Jr. (D-NJ) and co-sponsored by Congressman Charles Dent (R-PA) and Congressman John Delaney (D-MD) in Washington D.C on Sept 29th.…
Read more


MPLN expands their oncology testing repertoire with PD-L1 and PD-1 immunohistochemistry assays

Posted on August 11 2016 by J Seabrook

Molecular Pathology Laboratory Network Inc. launches Ventana PD-L1 and PD-1 assays, expanding their oncology immunohistochemistry menu of tests for NSCLC and other tumor types. MPLN’s repertoire of integrated testing now includes the addition…
Read more


MPLN partners with ArcherDX to offer ArcherĀ® NGS assays to global biopharma

Posted on July 19 2016 by J Seabrook

Boulder, COLORADO – ArcherDX, Inc., has announced that Molecular Pathology Laboratory Network, Inc. (MPLN) is now a Certified Service Provider of Archer® FusionPlex® NGS assays. MPLN will offer a custom sarcoma analysis service that…
Read more

1 2 3 4 5 6 7 8